SanBio Asia

SanBio is a regenerative medicine company focused on the development and commercialization of cell-based therapies for neurological disorders. The company's lead product, Vandefitemcel (SB623), consists of modified mesenchymal stem cells designed to promote neural regeneration following brain injuries. In 2024, SanBio received conditional and time-limited approval in Japan for SB623 for the treatment of traumatic brain injury, marking a significant milestone in the field of regenerative neurology. The company operates primarily out of Tokyo, Japan, and Mountain View, California, targeting high-unmet-need conditions such as stroke and traumatic brain injury.